Dermatomyositis is characterized by TYK2-dependent STAT3 activation
Clinical and Experimental Immunology · 06.01.2026 · 220 (1)
DOI: 10.1093/cei/uxag025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 08.07.2026. Verfasst von M Fornaro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Bari, Italy. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, TYK2 Kinase, Dermatomyositis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Dermatomyositis (DM) is characterized by activation of cytokine pathways that signal through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) axis, although the relative contribution of individual JAK family members remains unclear. Peripheral blood mononuclear cells were isolated from patients with active DM (n = 5), rheumatoid arthritis (RA, n = 7), systemic sclerosis (SSc, n = 7), and healthy donors (HD, n = 5). Phosphorylated STAT3 (pSTAT3) levels were assessed by flow cytometry in CD4+ and CD14+ cells under basal conditions and following selective inhibition of JAK1 (abrocitinib), JAK2 (gandotinib), JAK3 (decernotinib), or TYK2 (deucravacitinib). Under basal conditions, DM displayed the highest pSTAT3 levels in CD4+ cells (median 38.3%), significantly exceeding those observed in HDs (0.9%, P < 0.05) and SSc (8.6%, P < 0.05), while RA showed intermediate levels (17.7%). CD14+ cells from DM patients also demonstrated increased pSTAT3 compared with HDs (9.7% vs 1.4%, P < 0.05), without significant differences versus RA or SSc. Selective JAK inhibition revealed distinct disease-specific patterns. In DM, only TYK2 inhibition significantly reduced pSTAT3 levels in both CD4+ and CD14+ cells (P < 0.05), whereas in RA, pSTAT3 was modulated by inhibition of multiple JAK family members. No significant effects were observed in HDs or SSc patients. These findings identify a selective TYK2-dependent STAT3 activation signature in circulating immune cells from patients with DM, distinguishing this disease from other autoimmune conditions and supporting TYK2 as a potential therapeutic target in DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica (DiMePRe-J), University of Bari, Bari, Italy.
- Rheumatology Service, F. Miulli Hospital, Casamassima, Bari, Italy.
- Department of Medicine and Surgery, LUM University, Casamassima, Bari, Italy.
- Unit of Human Anatomy and Histology, Department of Translational Biomedicine and Neuroscience 'DiBraiN', University of Bari, Bari, Italy.
ORCID-Profile: M Fornaro, F Cacciapaglia, F Girolamo
Zitieren
APA
Fornaro, M., Del Vescovo, S., Cacciapaglia, F., Girolamo, F., Bizzoca, R., Natuzzi, D., & Iannone, F. (2026). Dermatomyositis is characterized by TYK2-dependent STAT3 activation. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag025
Vancouver
Fornaro M, Del Vescovo S, Cacciapaglia F, Girolamo F, Bizzoca R, Natuzzi D, et al. Dermatomyositis is characterized by TYK2-dependent STAT3 activation. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag025
BibTeX
@article{Fornaro2026,
author = {Fornaro, M and Del Vescovo, S and Cacciapaglia, F and Girolamo, F and Bizzoca, R and Natuzzi, D and Iannone, F},
title = {Dermatomyositis is characterized by TYK2-dependent STAT3 activation},
journal = {Clinical and Experimental Immunology},
year = {2026},
volume = {220},
number = {1},
doi = {10.1093/cei/uxag025}
}
EUVIMED